[go: up one dir, main page]

WO2008132464A3 - Procédés - Google Patents

Procédés Download PDF

Info

Publication number
WO2008132464A3
WO2008132464A3 PCT/GB2008/001469 GB2008001469W WO2008132464A3 WO 2008132464 A3 WO2008132464 A3 WO 2008132464A3 GB 2008001469 W GB2008001469 W GB 2008001469W WO 2008132464 A3 WO2008132464 A3 WO 2008132464A3
Authority
WO
WIPO (PCT)
Prior art keywords
mek5
module
erk5
mef
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/001469
Other languages
English (en)
Other versions
WO2008132464A2 (fr
Inventor
John R Mayer
Weng Choon Chan
Zahra Nooshin Rezvani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham filed Critical University of Nottingham
Publication of WO2008132464A2 publication Critical patent/WO2008132464A2/fr
Publication of WO2008132464A3 publication Critical patent/WO2008132464A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de diagnostic, de surveillance ou d'imagerie d'une maladie neurodégénérative dans un individu, le procédé comprenant la mesure des taux d'un ou plusieurs composants du module MEK5/ERK5/MEF, ou d'un activateur du module MEK5/ERK5/MEF, ou le taux d'un ou plusieurs composants du module MEK3/p38 MAPK, dans un échantillon de fluide corporel ou de tissu provenant de l'individu. L'invention concerne également un procédé de détection de composés utiles pour le diagnostic, la surveillance, l'imagerie ou le traitement d'une maladie neurodégénérative, le procédé comprenant la mise en contact d'un composé à tester avec un élément du module MEK5/ERK5/MEF et le dosage pour une augmentation de l'activité du module MEK5/ERK5/MEF. L'invention concerne en outre l'utilisation d'un composant du module MEK5/ERK5/MEF ou d'un activateur du module MEK5/ERK5/MEF ou du module MEK3/p38 MAPK dans un procédé de détection de composés utiles pour le diagnostic, la surveillance, l'imagerie ou le traitement d'une maladie neurodégénérative.
PCT/GB2008/001469 2007-04-26 2008-04-25 Procédés Ceased WO2008132464A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0708075.7 2007-04-26
GBGB0708075.7A GB0708075D0 (en) 2007-04-26 2007-04-26 Nethods

Publications (2)

Publication Number Publication Date
WO2008132464A2 WO2008132464A2 (fr) 2008-11-06
WO2008132464A3 true WO2008132464A3 (fr) 2009-04-02

Family

ID=38170720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001469 Ceased WO2008132464A2 (fr) 2007-04-26 2008-04-25 Procédés

Country Status (2)

Country Link
GB (1) GB0708075D0 (fr)
WO (1) WO2008132464A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100105776A (ko) 2008-01-18 2010-09-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
BR112013001752A2 (pt) 2010-07-23 2016-05-31 Harvard College método de detectar doenças ou condições usando células fagocídicas
EP2596353A4 (fr) 2010-07-23 2014-01-15 Harvard College Méthodes de dépistage de maladies ou d'affections prénatales ou liées à la grossesse
EP4303584A3 (fr) 2010-07-23 2024-04-03 President and Fellows of Harvard College Procédés de détection de signatures de maladies ou pathologies dans des liquides biologiques
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
WO2013188828A1 (fr) 2012-06-15 2013-12-19 Harry Stylli Méthodes de détection de maladies ou d'états au moyen de cellules infectées en circulation
EP2965086A4 (fr) 2013-03-09 2017-02-08 Harry Stylli Procédés de détection du cancer de la prostate
EP2965077B1 (fr) 2013-03-09 2022-07-13 Harry Stylli Procédés de détection de cancer
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
GB201407132D0 (en) * 2014-04-23 2014-06-04 Velgene Biotechnology Marker for neurodegenerative disorders
EP3693742B1 (fr) 2014-09-11 2022-04-06 Harry Stylli Procédés pour détecter le cancer de la prostate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021781A2 (fr) * 1993-03-19 1994-09-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Kinase extracellulaire a regulation par sequence signal, sequences, et procedes de production et d'utilisation
WO2002067764A2 (fr) * 2001-02-27 2002-09-06 Blanchette Rockefeller Neurosciences Institute Diagnostic de la maladie d'alzheimer base sur la phosphorylation d'une proteine kinase activee par mitogene
WO2006010514A2 (fr) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021781A2 (fr) * 1993-03-19 1994-09-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Kinase extracellulaire a regulation par sequence signal, sequences, et procedes de production et d'utilisation
WO2002067764A2 (fr) * 2001-02-27 2002-09-06 Blanchette Rockefeller Neurosciences Institute Diagnostic de la maladie d'alzheimer base sur la phosphorylation d'une proteine kinase activee par mitogene
WO2006010514A2 (fr) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEATRICE TERNI ET AL: "Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer's disease", ACTA NEUROPATHOLOGICA, SPRINGER, BERLIN, DE, vol. 113, no. 4, 20 January 2007 (2007-01-20), pages 403 - 416, XP019491136, ISSN: 1432-0533 *
DUDDERIDGE T J ET AL: "Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer", BRITISH JOURNAL OF CANCER, vol. 96, no. 9, 3 April 2007 (2007-04-03), pages 1384 - 1393, XP002493995, ISSN: 0007-0920 *
MAYER: "Ubiquitination and Alzheimer related disorders", HENRY STEWART TALKS-INTERNET ARTICLE, 1 October 2007 (2007-10-01), XP002493996, Retrieved from the Internet <URL:http://www.hstalks.com/main/browse_talk_info.php?talk_id=228&series_id=31> [retrieved on 20080827] *
MODY<A> N ET AL: "Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 502, no. 1-2, 27 July 2001 (2001-07-27), pages 21 - 24, XP004296812, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
GB0708075D0 (en) 2007-06-06
WO2008132464A2 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008132464A3 (fr) Procédés
EP2319941A3 (fr) Procédé et appareil pour corréler des niveaux de produits biomarqueurs avec une maladie
WO2007126444A3 (fr) Surveillance d&#39;analyte
ATE438853T1 (de) Diagnostische testvorrichtung
WO2009132058A3 (fr) Niveaux d’expression de la protéine bcma sur les lymphocytes b et utilisation dans de méthodes diagnostiques
BR112013006764A2 (pt) método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente
WO2009092386A8 (fr) Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
WO2008114224A3 (fr) Procédé et dispositif pour mesure de substance
JP2009501333A5 (fr)
EP2770328A3 (fr) Procédé pour diagnostiquer le cancer du pancréas
ATE491953T1 (de) Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
WO2006073682A3 (fr) Test diagnostique
WO2008091814A3 (fr) Évaluation de l&#39;asthme et d&#39;une expression d&#39;un gène dépendant d&#39;un allergène
EP2166360A3 (fr) Systèmes d&#39;essai d&#39;analytes
ATE537454T1 (de) Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
WO2011123775A3 (fr) Procédés, systèmes et dispositifs pour l&#39;analyse de données relatives à un patient
HK1213892A1 (zh) Tec家族激酶抑制剂疗法的伴随诊断
WO2011021041A3 (fr) Dosage pronostique de détermination de la survie
EP2535006A3 (fr) Dispositif médical pour la caractérisation et le traitement de tissus
EP2644588A3 (fr) Biomarqueurs pour le diagnostic de la sclérose en plaques et procédés associés
WO2005071407A3 (fr) Methodes
WO2007015113A3 (fr) Nouveaux isoformes de proteines et leurs utilisations
WO2012167887A8 (fr) Utilisation diagnostique de la prosomatostatine
WO2007079301A3 (fr) Procédé de diagnostic d&#39;une condition ou d&#39;une prédisposition de poids d&#39;un corps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08737114

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08737114

Country of ref document: EP

Kind code of ref document: A2